The additive effect of vitamin K supplementation and bisphosphonate on fracture risk in post-menopausal osteoporosis: a randomised placebo controlled trial.
Study Goal
The researchers aimed to determine whether vitamin K supplementation, when combined with calcium and/or vitamin D and bisphosphonate, had an additive effect on bone mineral density and fracture risk in post-menopausal women with osteoporosis.
Results Summary
The study found no significant differences in bone mineral density or bone turnover markers between groups receiving vitamin K supplementation and those not receiving it, suggesting no additive effect of vitamin K when combined with calcium and/or vitamin D and bisphosphonate.
Population
Post-menopausal women with osteoporosis and sub-optimal vitamin K status (average age 68.7 years).
Effective Dosage
Not specified
Duration
Not specified
Interactions
Bisphosphonate, vitamin D
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
vitamin K, given with oral bisphosphonate, calcium and/or vitamin D | decrease | fracture risk | post-menopausal women with osteoporosis | - | has an additive effect | #1 |
vitamin K | no change | bone density or bone turnover | post-menopausal women with osteoporosis | - | No difference | #2 |
vitamin K | decrease | bone loss | - | - | prevents | #3 |
vitamin K | decrease | fracture risk | - | - | may improve | #4 |
vitamin K supplementation | increase | bone mineral density (BMD), hip geometry and bone turnover markers (BTMs) | post-menopausal women with osteoporosis (PMO) and sub-optimum vitamin K status receiving bisphosphonate, calcium and/or vitamin D treatment | - | has an additive effect | #5 |
vitamin K | no change | BMD at the total hip, femoral neck and lumbar spine and BTMs; CTX and P1NP | 105 women aged 68.7[12.3] years with PMO and serum vitamin K | - | did not differ significantly | #6 |
vitamin K | no change | BMD at the total hip, femoral neck and lumbar spine and BTMs; CTX and P1NP | 105 women aged 68.7[12.3] years with PMO and serum vitamin K | - | did not differ significantly | #7 |
UNLABELLED: This study assessed whether vitamin K, given with oral bisphosphonate, calcium and/or vitamin D has an additive effect on fracture risk in post-menopausal women with osteoporosis. No difference in bone density or bone turnover was observed although vitamin K PURPOSE: Some clinical studies have suggested that vitamin K prevents bone loss and may improve fracture risk. The aim was to assess whether vitamin K supplementation has an additive effect on bone mineral density (BMD), hip geometry and bone turnover markers (BTMs) in post-menopausal women with osteoporosis (PMO) and sub-optimum vitamin K status receiving bisphosphonate, calcium and/or vitamin D treatment. METHODS: We conducted a trial in 105 women aged 68.7[12.3] years with PMO and serum vitamin K RESULTS: Changes in BMD at the total hip, femoral neck and lumbar spine and BTMs; CTX and P1NP did not differ significantly following either K CONCLUSION: The addition of vitamin K TRIAL REGISTRATION: The study was registered at Clinicaltrial.gov:NCT01232647.